(AME) Ametek - Overview
Stock: Instruments, Sensors, Power, Connectors, Motors
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.68% |
| Yield on Cost 5y | 1.12% |
| Yield CAGR 5y | 11.58% |
| Payout Consistency | 94.5% |
| Payout Ratio | 17.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 20.7% |
| Relative Tail Risk | -9.79% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.78 |
| Alpha | 9.62 |
| Character TTM | |
|---|---|
| Beta | 0.803 |
| Beta Downside | 0.852 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.04% |
| CAGR/Max DD | 0.70 |
Description: AME Ametek January 28, 2026
AMETEK (NYSE:AME) operates two primary divisions: Electronic Instruments Group (EIG) and Electromechanical Group (EMG). EIG supplies advanced measurement and control hardware to process, aerospace, power, and industrial markets, covering applications from oil-and-gas analytics to semiconductor test equipment and UAV sensors. EMG focuses on engineered medical components, specialty metals, thermal-management systems, precision motion-control products, and a network of aviation MRO facilities, serving sectors ranging from healthcare to defense and commercial appliances.
In FY 2023 the company reported $6.1 billion in revenue, a 5% YoY increase, with an adjusted operating margin of 14% and a free-cash-flow conversion of 78%. The order backlog stood at $2.3 billion, indicating roughly 12 months of visible demand. Key macro drivers include a 6% rise in U.S. defense spending (supporting aerospace and MRO sales), a 5% CAGR in global industrial automation (benefiting EMG’s motion-control and thermal-management lines), and a sustained semiconductor equipment shortage that underpins demand for EIG’s test-and-measurement solutions.
For a data-rich, quantitative follow-up, you might explore ValueRay’s analyst model on AME to see how these fundamentals translate into projected valuation scenarios.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 1.47b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -1.26 > 1.0 |
| NWC/Revenue: 5.75% < 20% (prev 11.10%; Δ -5.35% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.77b > Net Income 1.47b |
| Net Debt (2.31b) to EBITDA (2.16b): 1.07 < 3 |
| Current Ratio: 1.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (231.7m) vs 12m ago -0.24% < -2% |
| Gross Margin: 36.18% > 18% (prev 0.35%; Δ 3582 % > 0.5%) |
| Asset Turnover: 46.30% > 50% (prev 46.79%; Δ -0.50% > 0%) |
| Interest Coverage Ratio: 23.01 > 6 (EBITDA TTM 2.16b / Interest Expense TTM 80.4m) |
Altman Z'' 5.51
| A: 0.03 (Total Current Assets 3.06b - Total Current Liabilities 2.65b) / Total Assets 16.18b |
| B: 0.74 (Retained Earnings 11.92b / Total Assets 16.18b) |
| C: 0.12 (EBIT TTM 1.85b / Avg Total Assets 15.47b) |
| D: 2.03 (Book Value of Equity 11.49b / Total Liabilities 5.66b) |
| Altman-Z'' Score: 5.51 = AAA |
Beneish M -2.79
| DSRI: 1.30 (Receivables 1.31b/968.2m, Revenue 7.16b/6.91b) |
| GMI: 0.98 (GM 36.18% / 35.41%) |
| AQI: 1.00 (AQ_t 0.74 / AQ_t-1 0.74) |
| SGI: 1.04 (Revenue 7.16b / 6.91b) |
| TATA: -0.02 (NI 1.47b - CFO 1.77b) / TA 16.18b) |
| Beneish M-Score: -2.79 (Cap -4..+1) = A |
What is the price of AME shares?
Over the past week, the price has changed by +1.47%, over one month by +8.19%, over three months by +13.11% and over the past year by +21.23%.
Is AME a buy, sell or hold?
- StrongBuy: 10
- Buy: 2
- Hold: 5
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the AME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 232.4 | 3.8% |
| Analysts Target Price | 232.4 | 3.8% |
| ValueRay Target Price | 258.9 | 15.6% |
AME Fundamental Data Overview January 31, 2026
P/E Forward = 29.0698
P/S = 7.3055
P/B = 4.9558
P/EG = 2.9054
Revenue TTM = 7.16b USD
EBIT TTM = 1.85b USD
EBITDA TTM = 2.16b USD
Long Term Debt = 1.43b USD (from longTermDebt, last quarter)
Short Term Debt = 1.10b USD (from shortTermDebt, last quarter)
Debt = 2.75b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.31b USD (from netDebt column, last quarter)
Enterprise Value = 54.65b USD (52.34b + Debt 2.75b - CCE 439.2m)
Interest Coverage Ratio = 23.01 (Ebit TTM 1.85b / Interest Expense TTM 80.4m)
EV/FCF = 33.27x (Enterprise Value 54.65b / FCF TTM 1.64b)
FCF Yield = 3.01% (FCF TTM 1.64b / Enterprise Value 54.65b)
FCF Margin = 22.93% (FCF TTM 1.64b / Revenue TTM 7.16b)
Net Margin = 20.50% (Net Income TTM 1.47b / Revenue TTM 7.16b)
Gross Margin = 36.18% ((Revenue TTM 7.16b - Cost of Revenue TTM 4.57b) / Revenue TTM)
Gross Margin QoQ = 36.25% (prev 35.76%)
Tobins Q-Ratio = 3.38 (Enterprise Value 54.65b / Total Assets 16.18b)
Interest Expense / Debt = 0.82% (Interest Expense 22.5m / Debt 2.75b)
Taxrate = 17.09% (76.5m / 448.0m)
NOPAT = 1.53b (EBIT 1.85b * (1 - 17.09%))
Current Ratio = 1.16 (Total Current Assets 3.06b / Total Current Liabilities 2.65b)
Debt / Equity = 0.26 (Debt 2.75b / totalStockholderEquity, last quarter 10.53b)
Debt / EBITDA = 1.07 (Net Debt 2.31b / EBITDA 2.16b)
Debt / FCF = 1.40 (Net Debt 2.31b / FCF TTM 1.64b)
Total Stockholder Equity = 10.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.49% (Net Income 1.47b / Total Assets 16.18b)
RoE = 14.49% (Net Income TTM 1.47b / Total Stockholder Equity 10.14b)
RoCE = 15.99% (EBIT 1.85b / Capital Employed (Equity 10.14b + L.T.Debt 1.43b))
RoIC = 12.53% (NOPAT 1.53b / Invested Capital 12.24b)
WACC = 8.46% (E(52.34b)/V(55.09b) * Re(8.87%) + D(2.75b)/V(55.09b) * Rd(0.82%) * (1-Tc(0.17)))
Discount Rate = 8.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.03%
[DCF Debug] Terminal Value 79.54% ; FCFF base≈1.66b ; Y1≈2.01b ; Y5≈3.30b
Fair Price DCF = 212.4 (EV 51.21b - Net Debt 2.31b = Equity 48.90b / Shares 230.2m; r=8.46% [WACC]; 5y FCF grow 22.85% → 2.90% )
EPS Correlation: 82.22 | EPS CAGR: 8.96% | SUE: 4.0 | # QB: 16
Revenue Correlation: 94.84 | Revenue CAGR: 6.33% | SUE: 2.21 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.90 | Chg30d=+0.003 | Revisions Net=+4 | Analysts=12
EPS next Year (2026-12-31): EPS=8.00 | Chg30d=+0.021 | Revisions Net=+5 | Growth EPS=+8.7% | Growth Revenue=+7.8%